The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

General and administrative (G&A) expenses for the third quarters of 2024 and 2023 remained relatively stable at $1.8 million. The net loss for the third quarter of 2024 was $4.9 million, or $0.49 per ...

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs ... 36 days in a phase 1 readout in September. Metsera has ...

Supplements promising similar results to Ozempic have taken over social media, but the TGA and health experts have concerns.

potential once-monthly injectable GLP-1 RA engineered with Metsera’s HALO™ lipidation platform. MET-097i showed a 7.5% reduction in body weight from baseline at day 36 and a 380-hour half-life.